Recurrent livedo-like skin lesions following a vector-based COVID-19 vaccine
© 2023. The Author(s)..
Starting in 2020, the global health system faced unprecedent challenges due to the coronavirus disease 2019 (COVID-19) pandemic and the consequences are still felt. All the more fascinating and of particular importance for health policy was the development of potent vaccines within about one year by several research groups after the first reports of COVID-19 infections. To date, three types of COVID-19 vaccines are available, i.e., messenger RNA-based vaccines, adenoviral vector vaccines, and inactivated whole-virus vaccines. We report a woman who developed reddish, partially urticarial skin lesions on her right arm and flank shortly after the first dose with the corona vaccination from AstraZeneca/Oxford (ChAdOx1). The lesions were transient, however reoccurred in loco and at other locations over several days. The clinical presentation was unusual and was correctly assigned due to the clinical course.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Dermatologie (Heidelberg, Germany) - 74(2023), 8 vom: 26. Aug., Seite 614-617 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Rezidivierende Livedo-artige Hautveränderungen nach einer Vektor-basierten COVID-19-Impfung |
|---|
| Beteiligte Personen: |
Kränke, Teresa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse event |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 23.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00105-023-05160-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357394046 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357394046 | ||
| 003 | DE-627 | ||
| 005 | 20231226072509.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00105-023-05160-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357394046 | ||
| 035 | |a (NLM)37237145 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Kränke, Teresa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recurrent livedo-like skin lesions following a vector-based COVID-19 vaccine |
| 246 | 3 | 3 | |a Rezidivierende Livedo-artige Hautveränderungen nach einer Vektor-basierten COVID-19-Impfung |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 23.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Starting in 2020, the global health system faced unprecedent challenges due to the coronavirus disease 2019 (COVID-19) pandemic and the consequences are still felt. All the more fascinating and of particular importance for health policy was the development of potent vaccines within about one year by several research groups after the first reports of COVID-19 infections. To date, three types of COVID-19 vaccines are available, i.e., messenger RNA-based vaccines, adenoviral vector vaccines, and inactivated whole-virus vaccines. We report a woman who developed reddish, partially urticarial skin lesions on her right arm and flank shortly after the first dose with the corona vaccination from AstraZeneca/Oxford (ChAdOx1). The lesions were transient, however reoccurred in loco and at other locations over several days. The clinical presentation was unusual and was correctly assigned due to the clinical course | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adverse event | |
| 650 | 4 | |a Immunization | |
| 650 | 4 | |a Infection | |
| 650 | 4 | |a Skin diseases | |
| 650 | 4 | |a Urticaria | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 700 | 1 | |a Cerpes, Urban |e verfasserin |4 aut | |
| 700 | 1 | |a Legat, Franz |e verfasserin |4 aut | |
| 700 | 1 | |a Arbab, Emad |e verfasserin |4 aut | |
| 700 | 1 | |a Kränke, Birger |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatologie (Heidelberg, Germany) |d 2022 |g 74(2023), 8 vom: 26. Aug., Seite 614-617 |w (DE-627)NLM330027379 |x 2731-7013 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2023 |g number:8 |g day:26 |g month:08 |g pages:614-617 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00105-023-05160-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2023 |e 8 |b 26 |c 08 |h 614-617 | ||